Clinical Trials Sponsored by Caldera Medical, Inc.

Total 2829 results

Caldera Medical, Inc.

Recruiting

Desara ® One Single Incision Sling 522 Study

Stress Urinary Incontinence

United States
Calibra Medical, Inc.
Medpace, Inc.

Completed

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, France, United Kingdom, Germany
Aldeyra Therapeutics, Inc.

Completed

A Study in Subjects With Retinitis Pigmentosa

Retinitis Pigmentosa

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

Canada
Aldeyra Therapeutics, Inc.

Completed

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis | Seasonal Allergies

Canada
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Aldeyra Therapeutics, Inc.

Completed

A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

Non-infectious Anterior Uveitis

United States
Aldeyra Therapeutics, Inc.

Completed

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Sjogren-Larsson Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Dry Eye Syndromes

Canada
Aldeyra Therapeutics, Inc.

Completed

An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease

Dry Eye

Canada
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Aldeyra Therapeutics, Inc.

Withdrawn

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Nephrotic Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Chronic Cough

United States
Aldeyra Therapeutics, Inc.

Completed

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

Proliferative Vitreoretinopathy

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Assess Subjects With Dry Eye Disease.

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels

Ethanol Intoxication

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Aldeyra Therapeutics, Inc.

Completed

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

Sjögren-Larsson Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Covid19

United States
Aldeyra Therapeutics, Inc.

Completed

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

Non-infectious Anterior Uveitis

United States
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Recruiting

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Atopic Dermatitis

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Aldeyra Therapeutics, Inc.

Completed

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

Allergic Conjunctivitis

Canada
Aldeyra Therapeutics, Inc.

Completed

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

Dry Eye

United States
Galera Therapeutics, Inc.

Terminated

Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

Esophagitis

United States
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Renal Impairment

United States
Galera Therapeutics, Inc.

Terminated

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1)

NSCLC | SBRT | Non-metastatic

United States
Galera Therapeutics, Inc.

Completed

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Oral Mucositis

United States, Puerto Rico, Canada
Galera Therapeutics, Inc.

Completed

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

Head and Neck Cancer | Oral Mucositis

Spain, Switzerland, Belgium, Poland, Germany, Czechia
Galera Therapeutics, Inc.

Terminated

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Covid19 | SARS-CoV-2 Infection

United States
Galera Therapeutics, Inc.

Completed

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Radiation Induced Oral Mucositis

United States, Canada, Puerto Rico
Galera Therapeutics, Inc.

Completed

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx

United States
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Galera Therapeutics, Inc.

Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Unresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRT

United States, France, United Kingdom, Canada
Galera Therapeutics, Inc.

Completed

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Healthy Volunteers

Australia
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

Healthy

United States
Alder Biopharmaceuticals, Inc.

Completed

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2)

Migraine Disorders

United States, Belgium, Italy, Spain, United Kingdom, Germany, Hungary, Georgia, Slovakia, Russian Federation, Ukraine, Denmark, Czechia
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Chronic Migraine

Migraine Disorders

United States, Georgia, Australia, New Zealand
Alder Biopharmaceuticals, Inc.

Completed

Safety Tolerability and Pharmacokinetics of ALD403

Migraine Disorders

Australia
Alder Biopharmaceuticals, Inc.

Completed

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)

Migraine Disorder

United States
Ladera Medical
Avania

Not yet recruiting

The Ladera Large Bore Closure Feasibility Study

Vascular Closure | Femoral Arteriotomy Closure
Galera Therapeutics, Inc.
Celerion

Completed

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

Healthy | Healthy Volunteers

United States

3

Subscribe